The Use of Near-Infrared Light-Emitting Fluorescent Nanodiamond Particles to Detect Ebola Virus Glycoprotein: Technology Development and Proof of Principle
dc.creator | Feuerstein, GZ | |
dc.creator | Mansfield, MA | |
dc.creator | Lelkes, PI | |
dc.creator | Alesci, S | |
dc.creator | Marcinkiewicz, C | |
dc.creator | Butlin, N | |
dc.creator | Sternberg, M | |
dc.date.accessioned | 2020-12-10T18:03:27Z | |
dc.date.available | 2020-12-10T18:03:27Z | |
dc.date.issued | 2020-01-01 | |
dc.identifier.issn | 1178-2013 | |
dc.identifier.issn | 1178-2013 | |
dc.identifier.doi | http://dx.doi.org/10.34944/dspace/4262 | |
dc.identifier.other | 33116489 (pubmed) | |
dc.identifier.uri | http://hdl.handle.net/20.500.12613/4280 | |
dc.description.abstract | © 2020 Feuerstein et al. Background: There is a dire need for rapid diagnostic tests of high sensitivity, efficiency, and point-of-test reporting capability to mitigate lethal viral epidemic outbreaks. Purpose: To develop a new operating system within the lateral flow assay (LFA) format for Ebola virus (EBOV), based on fluorescent nanodiamond particles (FNDP) nitrogen vacancy (NV) emitting near-infrared (NIR) light. Specifically, we aimed to detail technical issues and the feasibility of mobilizing FNDP-NV on nitrocellulose membranes (NCM) and capturing them at test and control lines. Methods: FNDP-NV-200nm, 400nm or 800nm were linked to anti-EBOV glycoprotein (GP) monoclonal antibodies (mAb) and tested for LFA performance by monitoring NIR emissions using an in vivo imaging system or optoelectronic device (OED). Anti-EBOV recombinant glycoprotein (GP) humanized mAb c13C6 was linked to FNDP-NV-200nm for the mobile phase; and a second anti-GP mouse mAb, 6D8, was printed on NCM at the test line. Goat anti-human IgG (GAH-IgG) served as a nonspecific antibody for conjugated FNDP-NV-200nm at the control line. Results: FNDP-NV-200nm-c13C6 specifically and dose-dependently bound to recombinant EBOV GP in vitro and was effectively captured in a sandwich configuration at the test line by mAb 6D8. FNDP-NV-200nm-c13C6 was captured on the control line by GAH-IgG. The OED quantitative analysis of NIR (obtained in less than 1 minute) was further validated by an in vivo imaging system. Conclusion: FNDP-NV-200nm performance as a reporter for EBOV GP rapid diagnostic tests suggests an opportunity to replace contemporary visual tests for EBOV GP and other highly lethal viral pathogens. Mobile, battery-operated OED adds portability, quantitative data, rapid data collection, and point-of-test reporting capability. Further development of FNDP-NV-200nm within a LFA format is justified. | |
dc.format.extent | 7583-7599 | |
dc.language.iso | en | |
dc.relation.haspart | International journal of nanomedicine | |
dc.relation.isreferencedby | Informa UK Limited | |
dc.rights | CC BY-NC | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/3.0/ | |
dc.subject | Ebola virus | |
dc.subject | diagnostic lateral flow test | |
dc.subject | LFA | |
dc.subject | opto-electronic reader | |
dc.subject | OER | |
dc.subject | anti-EBOV antibodies | |
dc.subject | nitrocellulose membranes | |
dc.subject | fluidics technology | |
dc.title | The Use of Near-Infrared Light-Emitting Fluorescent Nanodiamond Particles to Detect Ebola Virus Glycoprotein: Technology Development and Proof of Principle | |
dc.type | Article | |
dc.type.genre | Journal Article | |
dc.relation.doi | 10.2147/IJN.S261952 | |
dc.ada.note | For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu | |
dc.creator.orcid | Lelkes, Peter|0000-0003-4954-3498 | |
dc.date.updated | 2020-12-10T18:03:22Z | |
refterms.dateFOA | 2020-12-10T18:03:28Z |